Can ZYN and IQOS Sustain Philip Morris' Smoke-Free Surge?

Philip Morris International's smoke-free business (SFB) is rapidly gaining scale, contributing 41% of net revenues and over 42% of gross profit in Q2 2025, with SFB net revenues up 15.2% and gross profit surging 23.3% year-over-year. This significant shift from combustibles is propelled by strong performances from IQOS, which saw 11.4% global sales growth and market share gains, and ZYN, which achieved 26% U.S. growth and 43% global shipment growth. This momentum highlights PM's successful strategic transformation and its leading position in the evolving nicotine delivery market.

Analysis

Philip Morris International's strategic pivot to its smoke-free business (SFB) is demonstrating significant financial traction, with the segment contributing 41% of total net revenues and over 42% of gross profit in the second quarter of 2025. The SFB's financial performance is robust, evidenced by a 15.2% year-over-year increase in net revenues and a 23.3% surge in gross profit, substantially outpacing the growth of the company's legacy combustible portfolio. This acceleration is driven by the dual engines of IQOS and ZYN. The IQOS heat-not-burn platform achieved 11.4% global sales growth and expanded its market share to 31.7% in Japan and 10.9% in Europe. Concurrently, the ZYN nicotine pouch brand is showing a powerful recovery in the U.S. with 26% offtake growth in Q2, while global shipments jumped 43%. Despite this strong fundamental performance and consensus estimates projecting double-digit earnings growth for 2025 (14%) and 2026 (12%), the company's stock has underperformed, declining 8.6% in the past month. This divergence is set against a premium valuation, with PM trading at a forward P/E of 20.26x compared to the industry average of 14.56x.

Key Decisions for Investors

• Investors should recognize that Philip Morris is successfully executing its strategic shift, with its high-growth, high-margin smoke-free business now a primary driver of overall financial performance.
• The recent 8.6% stock price decline, despite strong operational results, presents a potential valuation disconnect; however, this must be weighed against the stock's significant forward P/E premium relative to the industry.
• Monitor the competitive landscape in the nicotine pouch category, as strong shipment growth from Altria's on! (+26.5%) and aggressive expansion from Turning Point Brands could challenge ZYN's market dominance.
• The key forward-looking indicator will be the company's ability to sustain the growth momentum of both IQOS and ZYN to justify its premium valuation and meet the high consensus earnings growth expectations for 2025 and 2026.